Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05769764 · ClinicalTrials.gov registry record
A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer
A clinical trial, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- 225
- Enrollment target
NCT05769764: Completed study, sponsored by Daiichi Sankyo.
NCT05769764 is a clinical trial that has completed, run by Daiichi Sankyo. The registered enrollment target is 225 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05769764 has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- 225 participants
- Enrollment target
Study Summary
There is currently a lack of published HER3 expression prevalence data among non-small cell lung cancer (NSCLC) patients. The estimation of HER3 expression prevalence in this population using archival tissue samples and the assessment of associated patient characteristics in real world (RW) data will ultimately inform clinical strategy and increase awareness among health care providers (HCPs) and the greater medical community to improve patient care.
Primary Outcome
The overall HER3 expression prevalence estimate will be reported.
Interventions
- OTHER Archival tissue specimen and immunohistochemistry staining
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2022-12-19 |
| Est. Completion | 2023-04-06 |
What the finished NCT05769764 record still lists
NCT05769764 is an observational study that tracks outcomes without assigning an intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Archival tissue specimen and immunohistochemistry staining is the first listed.
NCT05769764 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05769764 about?
NCT05769764 is a clinical study titled "A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer". There is currently a lack of published HER3 expression prevalence data among non-small cell lung cancer (NSCLC) patients. The estimation of HER3 expression prevalence in this population using archival tissue samples and the assessment of associated patient characteristics in real world (RW) data wil...
What is the current status of trial NCT05769764?
This trial is currently completed. The enrollment target is 225 participants. The study started on 2022-12-19. Estimated completion is 2023-04-06.
What interventions are being tested in trial NCT05769764?
The interventions under investigation include: Archival tissue specimen and immunohistochemistry staining (OTHER).
Who is sponsoring clinical trial NCT05769764?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI